Breast Milk For Sale: Mothers Making Millions Online. But Is It Safe For Other Babies?
Women in the US are earning millions by selling breast milk, but is it safe for babies? Discover 5 essential facts about the benefits and risks of buying breast milk
Breastfeeding is on the rise across the United States, with an increasing number of women choosing to nurse their infants rather than rely on formula. As this trend gains momentum, an intriguing development has come to light: many women are now earning up to $1,000 (approximately Rs 87,000) per month by selling their surplus breast milk.
Online communities on platforms like WhatsApp and Facebook have emerged, where individuals prioritise purchasing breast milk over formula, believing it to offer superior health benefits. Remarkably, some bodybuilders are also reported to consume breast milk for its perceived nutritional value.
Why Is Breast Milk Considered Unique?
Health experts widely agree that breast milk offers numerous benefits for both the baby and the mother. It contains essential nutrients, antibodies, proteins, and healthy fats that support immunity and development. The first form of breast milk, colostrum, is often referred to as the baby's 'first vaccine' due to its protective qualities.
For babies, breast milk plays a vital role in both physical and cognitive development. For mothers, breastfeeding supports postpartum recovery, strengthens emotional bonding, and may reduce the risk of breast and ovarian cancer. It is also a safe, natural, and cost-effective source of nourishment during the early months of life.
The World Health Organisation (WHO) and UNICEF recommend exclusive breastfeeding for the first six months of a baby's life, citing its unmatched health benefits.
The Risks Of Buying Breast Milk
Despite its growing popularity, the US Food and Drug Administration (FDA) strongly advises against buying or feeding breast milk obtained from unregulated sources.
While sharing breast milk may appear harmless, it can pose serious health risks, especially if the donor's medical history is unknown.
Diseases such as HIV, hepatitis B and C, and various bacterial infections can be transmitted through breast milk.
Improper storage and handling can also lead to bacterial contamination, potentially making the milk unsafe or even fatal for infants.
Additionally, some sellers may engage in unhealthy practices to increase milk production, potentially compromising its nutritional quality.
Without proper medical supervision or laboratory testing, purchasing and using breast milk from informal sources can be highly risky.
A Global Phenomenon With Ongoing Debate
The trend of selling breast milk is not limited to the United States, it's observed in several other countries as well. However, the safety concerns highlighted by health authorities remain universally relevant.
As demand grows, so too does the debate about regulation, safety, and ethics surrounding the informal breast milk market.
Get breaking news, in-depth analysis, and expert perspectives on everything from geopolitics to diplomacy and global trends. Stay informed with the latest world news only on News18. Download the News18 App to stay updated!
view comments
First Published:
July 31, 2025, 11:28 IST
Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
SME IPO: Medistep Healthcare's Rs 16-cr public issue to open on Aug 8
Pharmaceutical firm Medistep Healthcare is set to raise a little over Rs 16 crore through its initial public offering ( IPO ), which opens for subscription on August 8. The company's maiden public issue will conclude on August 12. The shares are scheduled to be listed on the NSE SME platform on August 18, Medistep Healthcare said in a statement. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program The IPO comprises 37.44 lakh equity shares priced at a fixed Rs 43 per share, aggregating to a total issue size of Rs 16.09 crore. Following the listing, the company is expected to have a market capitalisation of Rs 61.10 crore. The company will utilise the proceeds of the IPO for purchase of plant and machinery for expansion of its existing manufacturing facility, working capital requirements and general corporate purposes. "Proceeds from the IPO will strategically support our expansion efforts and reinforce our footprint in both domestic and international markets," Girdhari Lal Prajapati, Managing Director at Medistep Healthcare, said. Live Events The company is in the business of manufacturing sanitary pads & energy powder, and trading of a diverse range of pharmaceutical products, nutraceutical products, intimate products and surgical products through a distribution network. On the financial front, the company recorded revenue from operations of Rs 49.65 crore in FY25, an increase from Rs 39.07 crore in the preceding fiscal. Its profit after tax (PAT) also rose to Rs 4.14 crore in FY25, compared to Rs 3.33 crore in the previous financial year. Fast Track Finsec is the sole lead manager of the public issue while Cameo Corporate Services is the registrar to the issue.
Hans India
an hour ago
- Hans India
District Administration Implements UNICEF Recommendations to Strengthen Child Welfare Services in Gadwal
Gadwal: District Collector B.M. Santhosh announced that the district administration is taking comprehensive measures to improve child welfare services in line with the recommendations made by the UNICEF team. On Tuesday, a review meeting on the implementation of the Supervised Supplementary Feeding Program was held at the IDOC Video Conference Hall. Officials from various departments, along with the UNICEF team, participated in the meeting. As part of their visit, the UNICEF team inspected the medicine store near the Gadwal Medical College, an Anganwadi center, and a Primary Sub-Center in Gattu Mandal. They evaluated the supply of medicines, the distribution of nutritional supplements, and the implementation of medical services. The UNICEF team briefed the Collector on their observations and appreciated the district's progress, particularly in identifying and addressing nutritional deficiencies among children. They lauded the district's effective mechanisms for detecting malnutrition in early stages. In response, the District Collector assured that all suggestions made by the UNICEF team would be carefully followed and used as a foundation to enhance the quality of services delivered at the district level. He emphasized that special attention would be given to children who are not responding to nutritional services or show signs of growth retardation, and appropriate corrective actions would be taken to restore their health. He further stated that awareness meetings would be conducted with self-help groups, Anganwadi workers, and ASHA workers to ensure a unified and coordinated approach. A clear and common message will be disseminated among all stakeholders to strengthen inter-departmental coordination. The Collector noted that, following UNICEF's guidance, the Supervised Supplementary Feeding Program will be implemented more effectively. Services such as distribution of Balamrutham Plus, medical support, nutrition, and health education will be delivered in a more integrated and efficient manner. The meeting was attended by Additional Collector Narsinga Rao, District Welfare Officer Sunanda, DPO Nagendram, District Medical Officer Siddappa, UNICEF team members, and other officials.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
